Home » Stocks » ATHE

Alterity Therapeutics Limited (ATHE)

Stock Price: $1.41 USD -0.05 (-3.10%)
Updated Oct 29, 2020 11:48 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 31.76M
Revenue (ttm) n/a
Net Income (ttm) -13.46M
Shares Out 22.60M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 29, 2020
Last Price $1.41
Previous Close $1.45
Change ($) -0.05
Change (%) -3.10%
Day's Open 1.42
Day's Range 1.34 - 1.44
Day's Volume 47,842
52-Week Range 0.28 - 5.15

More Stats

Market Cap 31.76M
Enterprise Value 22.60M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 22.60M
Float n/a
EPS (basic) -0.90
EPS (diluted) -0.90
FCF / Share -0.63
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5,150
Short Ratio 0.04
Short % of Float n/a
Beta 0.80
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.66
Revenue n/a
Operating Income -13.94M
Net Income -13.46M
Free Cash Flow -9.45M
Net Cash 9.16M
Net Cash / Share 0.41
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -58.40%
ROE -113.53%
ROIC -12,239.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $1.41
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-----19.33%-51.39%141.12%-19.18%19.55%-
Gross Profit----
Operating Income-13.94-17.75-11.32-10.04-13.34-16.92-20.40-11.10-6.55-5.43
Net Income-13.46-12.34-8.27-7.54-7.73-5.89-13.33-7.79-5.24-6.43
Shares Outstanding895616534534534503428339288248
Earnings Per Share-0.90-1.20-0.93-0.85-0.87-0.70-1.87-1.38-1.09-1.56
Operating Cash Flow-9.43-13.95-6.25-5.87-7.42-10.87-13.54-7.95-6.85-4.56
Capital Expenditures-0.02-0.01-0.06-0.03--0.03-0.02-0.02-0.03-0.01
Free Cash Flow-9.45-13.96-6.31-5.89-7.42-10.90-13.56-7.97-6.87-4.57
Cash & Equivalents9.2014.4015.2421.8828.5934.9134.1713.355.648.84
Total Debt0.03----
Net Cash / Debt9.1614.4015.2421.8828.5934.9034.0712.485.308.48
Book Value7.1516.5516.0823.6931.3739.1137.6913.975.626.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Alterity Therapeutics Limited
Employees 12
CEO Geoffrey Paul Kempler

Stock Information

Ticker Symbol ATHE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ATHE


Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.